Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jan;51(1):142–153. doi: 10.1124/dmd.122.000898

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

U.S. Government work not protected by U.S. copyright

PMC Copyright notice

Fig. 5. — Known and putative azo-reducing species are more abundant in the IBD gut. Relative abundance of known and putative azo-reducing species in HMP2 subjects with more than 20 total stool collections. (A) Relative abundance of known and putative azo-reducing species for qualifying participants across non-IBD, UC, and CD populations. Subjects with CD have significantly higher relative abundances of known+putative azo-reducing species than healthy subjects (non-IBD) per linear mixed-effects model ANOVA, F(1,10) = 17.09, P < 0.003. (B) Relative abundance of putative azo-reducing species over time for healthy (non-IBD), UC, and CD participants. Each line represents a single participant, and each point is the summed relative abundance of known+putative azo-reducing species at that collection point. The key on the right links relative abundance distributions for each subject with the same data point shown over collection numbers. Collections were taken approximately every 14 days.